NASDAQ:VERU - Veru Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.41 +0.12 (+9.30 %) (As of 04/22/2019 02:52 AM ET)Previous Close$1.41Today's Range$1.33 - $1.4152-Week Range$1.18 - $2.37Volume99,736 shsAverage Volume98,875 shsMarket Capitalization$88.45 millionP/E RatioN/ADividend YieldN/ABeta0.91 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Veru Inc. operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which is under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil and Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate. The company's oncology drug candidate includes VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-111, an oral alpha and beta tubulin inhibitor, which is under Phase 1b/2 study for the treatment of metastatic prostate, breast, endometrial, ovarian, and pancreatic cancers. It serves agencies, health care distributors, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida. Receive VERU News and Ratings via Email Sign-up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Fabricated rubber products, not elsewhere classified Sub-IndustryPersonal Products SectorMedical Current SymbolNASDAQ:VERU Previous Symbol CUSIP31446210 CIK863894 Webwww.veruhealthcare.com Phone305-509-6897Debt Debt-to-Equity Ratio0.08 Current Ratio1.58 Quick Ratio1.30Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$15.86 million Price / Sales5.58 Cash FlowN/A Price / Cash FlowN/A Book Value$0.53 per share Price / Book2.66Profitability EPS (Most Recent Fiscal Year)($0.39) Net Income$-23,930,000.00 Net Margins-111.10% Return on Equity-60.83% Return on Assets-41.10%Miscellaneous Employees171 Outstanding Shares62,730,000Market Cap$88.45 million Next Earnings Date5/8/2019 (Estimated) OptionableOptionable Veru (NASDAQ:VERU) Frequently Asked Questions What is Veru's stock symbol? Veru trades on the NASDAQ under the ticker symbol "VERU." How were Veru's earnings last quarter? Veru Inc (NASDAQ:VERU) posted its earnings results on Wednesday, February, 13th. The company reported ($0.03) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.04) by $0.01. The company had revenue of $6.37 million for the quarter, compared to analyst estimates of $9.71 million. Veru had a negative net margin of 111.10% and a negative return on equity of 60.83%. View Veru's Earnings History. When is Veru's next earnings date? Veru is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Veru. What price target have analysts set for VERU? 5 analysts have issued 1-year price objectives for Veru's stock. Their forecasts range from $4.50 to $6.00. On average, they expect Veru's share price to reach $5.1250 in the next twelve months. This suggests a possible upside of 263.5% from the stock's current price. View Analyst Price Targets for Veru. What is the consensus analysts' recommendation for Veru? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veru. What are Wall Street analysts saying about Veru stock? Here are some recent quotes from research analysts about Veru stock: 1. According to Zacks Investment Research, "Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. " (4/17/2019) 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $295M. This includes a discounted cash flow-based asset value of $305M for FC2 and Tamsulosin DRS, excluding $10M debt and using a 15% discount rate, 0% terminal growth rate and 60% probability of success for Tamsulosin DRS." (1/23/2019) 3. Maxim Group analysts commented, "Veru announced the company was awarded 75% of the South Africa female condom tender, or a total of 120M female condoms over three years. We view this news as a significant positive, as it will continue to help offset the R&D burn associated with the urology pipeline, which is where we see the most significant value and upside in Veru." (8/27/2018) Has Veru been receiving favorable news coverage? Media stories about VERU stock have trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Veru earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. Who are some of Veru's key competitors? Some companies that are related to Veru include Akorn (AKRX), Beyondspring (BYSI), Medical Developments International (MVP), Senseonics (SENS), Senseonics (SENS), Keryx Biopharmaceuticals (KERX), Unity Biotechnology (UBX), Kindred Biosciences (KIN), Agenus (AGEN), Clover (CLV), Savara (SVRA), MiMedx Group (MDXG), Geron (GERN), BioDelivery Sciences International (BDSI) and Solid Biosciences (SLDB). What other stocks do shareholders of Veru own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Corbus Pharmaceuticals (CRBP), Genocea Biosciences (GNCA), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Verastem (VSTM), Idera Pharmaceuticals (IDRA), Iovance Biotherapeutics (IOVA), Opko Health (OPK), Viking Therapeutics (VKTX) and Viewray (VRAY). Who are Veru's key executives? Veru's management team includes the folowing people: Dr. Mitchell S. Steiner M.D., F.A.C.S, Chairman, Pres & CEO (Age 58)Dr. Harry Fisch, Vice Chairman & Chief Corp. Officer (Age 60)Mr. O. B. Parrish, Co-Founder & Director (Age 86)Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 60)Dr. K. Gary Barnette Ph.D., Chief Scientific Officer (Age 51) Who are Veru's major shareholders? Veru's stock is owned by many different of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.10%). Company insiders that own Veru stock include Daniel Haines, David R Bethune, Elgar Peerschke, Harry Fisch, Jesus Socorro, K Gary Barnette, Lucy Lu, Mitchell Shuster Steiner and O B Parrish. View Institutional Ownership Trends for Veru. Which institutional investors are buying Veru stock? VERU stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Veru stock in the last two years include Daniel Haines, David R Bethune, Elgar Peerschke, Harry Fisch, Jesus Socorro, K Gary Barnette, Lucy Lu, Mitchell Shuster Steiner and O B Parrish. View Insider Buying and Selling for Veru. How do I buy shares of Veru? Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Veru's stock price today? One share of VERU stock can currently be purchased for approximately $1.41. How big of a company is Veru? Veru has a market capitalization of $88.45 million and generates $15.86 million in revenue each year. The company earns $-23,930,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Veru employs 171 workers across the globe. What is Veru's official website? The official website for Veru is http://www.veruhealthcare.com. How can I contact Veru? Veru's mailing address is 4400 Biscayne Boulevard Suite 888, Miami FL, 33137. The company can be reached via phone at 305-509-6897 or via email at [email protected] MarketBeat Community Rating for Veru (NASDAQ VERU)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 164 (Vote Outperform)Underperform Votes: 109 (Vote Underperform)Total Votes: 273MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote "Outperform" if you believe VERU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/22/2019 by MarketBeat.com StaffFeatured Article: Does the discount rate affect the economy?